Screening with Zenicor-ECG can save billions for Swedish Healthcare
During the European Digital Heart Congress ESC, the health economic results from the STROKESTOP study were presented for the first time. The study where the Zenicor-ECG was used to screen for atrial fibrillation with the aim of preventing stroke. The health economic results indicated that screening with the Zenicor-ECG is cost-effective and cost-saving for society. For every cohort of 75/76-year-olds in Sweden screened for atrial fibrillation, the costs for the society can be reduced by SEK 3.6 billion.
